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Few reliable data exist concerning the recurrence risk for individual trisomies or the risk for recurrence of trisomy
for a different chromosome. We collected records from two sources: (1) prenatal diagnoses performed at the Hoˆpital
Sainte-Justine in Montreal and (2) karyotype analyses performed at Genzyme. Using the standardized morbidity
ratio (SMR), we compared the observed number of trisomies at prenatal diagnosis with the expected numbers,
given maternal age–speciﬁc rates (by single year). SMRs were calculated both for recurrence of the same trisomy
(homotrisomy) and of a different trisomy (heterotrisomy). After all cases with an index trisomy 21 were combined,
the SMR for homotrisomy was 2.4 (90% CI 1.6–3.4; ). For women with both the index trisomy andPp .0005
subsequent prenatal diagnosis at age !30 years, the SMR was 8.0; it was 2.1 for women with both pregnancies at
age 30 years. For the other index viable trisomies (13, 18, XXX, and XXY) combined, the SMR for homotrisomy
was 2.5 (90% CI 0.7–8.0). For heterotrisomy, the SMR after an index trisomy 21 was 2.3 (90% CI 1.5–3.8,
); the SMR did not vary with maternal age at the ﬁrst trisomy. When all cases with index viable trisomiesPp .0007
were combined, the SMR for heterotrisomy was 1.6 (90% CI 1.1–2.4; ). For prenatal diagnoses followingPp .04
a nonviable trisomy diagnosed in a spontaneous abortion (from Genzyme data only), the SMR for a viable trisomy
was 1.8 (90% CI 1.1–3.0; ). The signiﬁcantly increased risk for heterotrisomy supports the hypothesis thatPp .04
some women have a risk for nondisjunction higher than do others of the same age.
Introduction
In spite of the large numbers of prenatal diagnoses per-
formed for the detection of trisomy, there are few reliable
data concerning the risk of recurrence for individual tri-
somies, and there are almost no data concerningwhether
a trisomic pregnancy is associated with an increased risk
for trisomy of a different chromosome.
Recurrence of trisomy in the same couple could occur
for several reasons: (1) chance alone, due to the mater-
nal age–associated risk, (2) parental gonadal mosaicism
for trisomy, or (3) factors associated with an increased
risk of meiotic error. In population studies, comparison
of the observed numbers of recurrences of the same or
a different trisomy with that expected on the basis of
maternal age can indicate whether chance alone can ac-
count for trisomy recurrences.
Trisomy mosaicism in a gonad may explain an in-
creased recurrence risk for trisomies of the same chromo-
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some (homotrisomy), producing a very high rate of re-
currence in a small number of families (Sachs et al.
1990). Mosaicism will be underestimated by studies of
parental lymphocytes (Uchida and Freeman 1985) or
genetic markers (Pangalos et al. 1992; Bruyere et al.
2000), which have suggested rates of ∼2% in cases of
Down syndrome. In contrast, gonadal mosaicism can-
not explain an increased recurrence risk for a different
trisomy (heterotrisomy). Rather, such an increase would
imply that some couples have a higher risk for meiotic
nondisjunction than do others of the same age. Since
most trisomy is of maternal origin (Hassold and Hunt
2001), maternal factors probably would be implicated.
Knowledge of whether some women are at increased
risk for meiotic error has both practical and theoretical
implications. From a practical standpoint, it inﬂuences
whether young women with a pregnancy loss known to
be trisomic should be offered prenatal diagnosis in fu-
ture pregnancies. From a theoretical standpoint, an in-
creased recurrence risk for meiotic nondisjunction in
general is predicted by many hypotheses concerning the
origins of the maternal-age association—for example,
genetic variation in recombination frequency (Brown et
al. 2000; Lynn et al. 2002), mutations in genes involved
in the meiotic process (Zwick et al. 1999; Schon et al.
2000; Arbuzova et al. 2001; Balicky et al. 2002), or
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Table 1
Number of Prenatal Diagnoses, by Karyotype, of the Index
Pregnancy: Sainte-Justine 1976–1999
KARYOTYPE
OF INDEX
PREGNANCYa
NO. OF
WOMEN
NO. OF AMNIOCENTESES PER
WOMAN
TOTAL
NO.
OF
PNDb1 2 3 4 5
Trisomy 21 503 359 121 20 2 1 674
Trisomy 18 93 51 38 4 0 0 139
Trisomy 13 59 42 16 1 0 0 77
XXX/XXY 6 6 0 0 0 0 6
45,X 78 50 18 9 1 0 117
Triploidy 9 6 2 0 1 0 14
Total 748 514 195 34 4 1 1,027
a Excludes cases with “other anomalies,” cases with two prior tri-
somies, and double trisomies.
b PND p prenatal diagnoses.
biological aging processes in the ovary, which might vary
among women of the same chronological age (Kline et
al. 2000; Hodges et al. 2002).
At present, genetic counseling concerning trisomy re-
currence is most often based on the analysis of European
amniocenteses collected in the 1980s (Stene et al. 1984;
reanalyzed by Warburton et al. [1987]). For trisomy 21,
these data showed that among women aged !30 years
at the time of prenatal diagnosis, the risk of recurrence
was ∼8 times the maternal age–associated risk, whereas,
for women who had their ﬁrst trisomy at age30 years,
the risk was not increased above that based on maternal
age. Data on trisomy recurrence have also been reported
from 273 women with two karyotyped spontaneous
abortions (Warburton et al. 1987). After adjustment for
maternal age, the odds ratio for a second trisomic preg-
nancy loss in women with a previous trisomic loss (com-
pared with a woman with no previous karyotyped loss)
was 1.3 (95% CI 0.7–2.1). These data suggested that
women having one pregnancy loss with trisomy were
not at increased risk for trisomy in a second pregnancy.
We collected data on trisomy recurrence from two
sources: (1) records of prenatal diagnoses performed over
a 20-year period in the Hoˆpital Sainte-Justine in Mon-
treal and (2) records of karyotype analyses performed
at Genzyme, based in Santa Fe, NM. These data conﬁrm
the large increase in risk for recurrence of trisomy 21
among young women, but they indicate that there is
also a doubling of risk among older women. They also
provide evidence of an increased risk for trisomy in
general following either a live birth with trisomy or a
pregnancy loss with trisomy.
Subjects and Methods
Subjects
Data on karyotypes from prenatal diagnoses (without
identiﬁers) were obtained from two cytogenetic labora-
tories:
1. Service de Ge´ne´tique Me´dicale, Hoˆpital Sainte-Jus-
tine, Montreal: At the Hoˆpital Sainte-Justine, all records
were derived from prenatal diagnosis by amniocentesis
performed between 1976 and 1999. Cases were women
for whom a previous trisomy, monosomy X, or triploidy
(the index case) was recorded as a reason for the prenatal
diagnosis; there was laboratory documentation of this
result; and the maternal age at both the previous index
pregnancy and the prenatal diagnosis were recorded.
Some women had more than one amniocentesis after
the index pregnancy. The ﬁnal sample consisted of
1,027 amniocenteses from 748 women with a history of
a previous numerical chromosome abnormality (table 1).
The source of these data has been described in a pre-
vious publication (Caron et al. 1999).
2. Genzyme Genetics, at various sites in the United
States: At Genzyme Genetics, we used a computerized
database to identify all women with two or more preg-
nancies karyotyped in Genzyme laboratories. These preg-
nancies included both prenatal diagnoses and sponta-
neous abortions. Cases were women for whom a ﬁrst
pregnancy with trisomy, monosomy X, or triploidy (the
index pregnancy) was followed by a prenatal diagnosis,
either by amniocentesis or chorionic villus sampling, dur-
ing the years 1994–2001. Maternal age was available in
all cases for both the index pregnancy and subsequent
prenatal diagnoses. Some women had more than one
subsequent prenatal diagnosis. The ﬁnal sample con-
sisted of 1,536 amniocenteses and 293 chorionic villus
samples from 1,702 women with a history of a previous
numerical chromosome abnormality (table 2).
In both samples, we excluded women with more than
one trisomy prior to the prenatal diagnosis, as well as
women whose index pregnancy had a double anomaly,
a monosomy other than X, a mosaic other than a tri-
somy/normal mosaic, or was 47,XYY (always paternally
derived). We included, as a comparison group, women
whose index abnormality was 45,X or triploid. Since the
mechanisms of origin of these anomalies are usually con-
sidered different from those of trisomy, we expect no
increase in trisomy above the maternal age–related rate.
Trisomy risk after these karyotypes is also sometimes an
issue in genetic counseling.
We refer to trisomies 13, 18, 21, X, and Y as “viable”
trisomies, since they can occur as nonmosaics at the time
of prenatal diagnosis and in live births. We refer to all
the other trisomies, which usually are found only in
spontaneous abortions, as “nonviable” trisomies. We re-
fer to trisomies XXX and XXY as “X-aneuploidy.”
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Table 2
Number of Prenatal Diagnoses, by Karyotype, of the Index Pregnancy: Genzyme 1994–2001
KARYOTYPE OF
INDEX CASEa
NO. OF
WOMEN
NO. OF PRENATAL DIAGNOSES
TOTAL
PNDb
First
Amniocentesis
First Chorionic
Villus Sample
Second
Amniocentesis
Second Chorionic
Villus Sample
Trisomy 21 657 518 139 46 8 711
Trisomy 18 235 198 37 15 2 252
Trisomy 13 132 113 19 6 0 138
XXX/XXY 48 40 8 2 4 54
POCc with trisomy 16 118 103 15 7 1 126
POCc with other trisomy 251 228 23 10 3 264
45,X 165 145 20 11 2 178
Triploid 96 83 13 10 0 106
Total 1,702 1,399 266 137 27 1,829
a Excludes double anomalies including hyper- and hypotriploids, mosaics except for trisomy/normal mosaics, and double
trisomies. Includes prenatal diagnoses subsequent to a spontaneous abortion following the index pregnancy.
b PND p prenatal diagnoses.
c POC p product of conception (spontaneous abortion).
Statistical Analysis
Expected numbers of trisomies by single year of ma-
ternal age.—Ages of women at the time of prenatal di-
agnosis ranged from 16 to 50 years. For women aged
33 years, age-speciﬁc (in single years) rates of trisomy
13, 18, 21, XXX, and XXY from amniocenteses and
chorionic villus samples in the United States are available
from data analyzed by Hook (1992) and Snijders (1994,
1999). We used the rates from Hook, but the two esti-
mates are very similar.
For women aged !33 years, there are no good esti-
mates of trisomy rates in prenatal diagnoses by single
year of maternal age. For trisomy 21, we converted data
on live-birth frequencies by single year (Hook 1992) into
rates at the time of prenatal diagnosis by correcting for
losses that occur between the time of prenatal diagnosis
and birth. For trisomy 21, there have been various es-
timates of this loss rate, after both amniocentesis and
chorionic villus biopsy (reviewed by Morris et al. 1999;
Snijders et al. 1999; Spencer 2001). For loss rates after
amniocentesis (15–29 wk) we used 23%, the rate esti-
mated by Morris et al. (1999) from a meta-analysis of
published studies, which is very similar to the latest ﬁg-
ure derived by Snijders et al. (1999). For chorionic villus
samples, we used 36%, the best estimate from the same
sources. We also tested the robustness of our analysis,
using higher and lower estimates of loss between pre-
natal diagnosis and birth: the expected values of trisomy
changed very little, because trisomy rates are so low
among young women. For example, changing the esti-
mated rate of loss between amniocentesis and birth from
23% to 36% after amniocentesis changes the expected
number of trisomy 21 cases in women aged !33 years
only in the second decimal place.
For viable trisomies other than 21, there are no age-
speciﬁc rates in single years for either live births or pre-
natal diagnoses for women younger than 33 years. For
trisomy 13 and 18, we used the estimates of Snijders et
al. (1999) for amniocenteses and chorionic villus sam-
ples. These estimates are based on the ratio of trisomy
13 and 18 to trisomy 21 in 5-year maternal-age cate-
gories. Hook et al. (1979) used the same method to es-
timate rates of trisomy 18 by single year of maternal age.
Since X-aneuploidy is not associated with fetal loss, and
there is little increase in the rate with age !33 years, we
used live-birth rates for these trisomies in 5-year mater-
nal-age categories (Hook 1992).
The validity of our estimates of expected values is
supported by the good agreement between the observed
and expected numbers of trisomies in the women with
a previous 45,X or triploid pregnancy (see the “Results”
section).
We performed the analyses both with and without the
inclusion of repeat prenatal diagnoses. No woman had
more than one trisomy in prenatal diagnoses subsequent
to the index trisomy.
The standardized morbidity ratio: comparison of ob-
served versus expected numbers of trisomies.—Cases
were classiﬁed by age at the time of prenatal diagnosis
and, for women with a previous trisomy 21, by age at
the birth or prenatal diagnosis of the index (preceding)
trisomy 21. Observed numbers were those recorded in
the data. We estimated the expected number of trisomy
21, trisomy 13, trisomy 18, and X-aneuploid prenatal
diagnoses at each age, using the single-year risks de-
scribed above. The total numbers of observed and ex-
pected trisomies were then summed over all maternal-
age categories. The recurrence risk, compared with the
age-associated risk, was estimated as the ratio of ob-
served to expected, which is equivalent to the standard-
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Table 3
Distribution of Prenatal Diagnoses by Maternal Age
MATERNAL
AGE
(years)
NO. (%) OF PRENATAL DIAGNOSES FROM
Genzyme Sample Sainte-Justine Sample
!20 6 (.3) 2 (.2)
20–24 40 (2.2) 105 (10.2)
25–29 163 (8.9) 366 (35.6)
30–34 386 (21.1) 332 (32.3)
35–39 854 (46.7) 194 (19.0)
40–44 370 (20.2) 26 (2.5)
45 10 (.6) 2 (.2)
Total 1,829 (100) 1,027 (100)
Table 4
Recurrence of Trisomy 21: Index Pregnancy at Maternal Age !30 Years
Maternal Age and Sample
No. of Prenatal
Diagnoses
Expected No.
of Trisomy 21
Observed No.
of Trisomy 21 SMRa 90% CI Pb
Prenatal diagnosis at age !30 years:
Genzyme 80 .094 2 21.3 5.7–68.9 .004
Sainte-Justine 342 .391 2 5.1 1.4–16.6 .059
Total prenatal diagnoses 422 .485 4 8.2 3.6–18.6 .002
Prenatal diagnosis at age 30 years:
Genzyme 23 .045 0 0 .0–66.5 1.0
Sainte-Justine 140 .344 0 0 .0–8.7 1.0
Total prenatal diagnoses 163 .389 0 0 .0–7.7 1.0
All prenatal diagnoses:
Genzyme 103 .139 2 14.4 3.8–46.6 .009
Sainte-Justine 482 .735 2 2.7 .7–8.8 .168
Total prenatal diagnoses 585 .874 4 4.6 2.0–10.3 .012
a Observed/expected.
b One-tailed exact P value.
ized morbidity ratio (SMR). Assuming a Poisson distri-
bution for the counts with the age-adjusted expectations,
we used an exact, one-tailed test of signiﬁcance (at
) to test whether there was a signiﬁcant excessap .05
of observed over expected trisomies. We also report the
corresponding one-tailed exact P values and—consistent
with one-tailed testing—exact, two-sided 90% CIs by
use of the point-probability method (Fleiss et al. 2003,
p. 37). We tested heterogeneity of the SMRs between
data sets, among maternal-age classes, and among tri-
somy classes, using the x2 statistic for binomial or multi-
nomial data, which is appropriate for independent Pois-
son variables conditional on their sum. The tests for het-
erogeneity were two-tailed, conducted at the .05 level of
signiﬁcance. We assessed the possibility of information
loss by the use of repeat entries from some women by
calculating the variance-inﬂation factor due to clustering
of repeat entries within those women (Fleiss et al. 2003,
pp. 213, 441). This factor was trivial in these data
(!.0004). Therefore, the analyses reported here include
both ﬁrst and repeat prenatal diagnoses without adjust-
ment for clustering.
Results
Distribution of Maternal Age
The mean maternal age is 30.1 years in the Sainte-
Justine sample and 35.7 years in the Genzyme sample
(table 3). This age disparity may partly reﬂect the earlier
time period covered in the Sainte-Justine sample and the
demographics of the catchment area. However, it is
probably largely because index trisomies in the Sainte-
Justine sample include live births, whereas the Genzyme
sample comprises only prenatal diagnoses or pregnancy
losses, which tend to occur at older maternal ages.
Homotrisomy
Data concerning recurrence of the same trisomy were
analyzed for cases in which the index pregnancy was
trisomy 21, trisomy 18, trisomy 13, or X-aneuploidy.
Since previous analyses had indicated a difference in risk
depending on the age at the ﬁrst trisomy, we also assessed
the effect of age at the ﬁrst trisomy and age at the sub-
sequent prenatal diagnoses for index trisomy 21 preg-
nancies. For other trisomies, the numbers were too small
to stratify by maternal age at index trisomy.
Tables 4 and 5 show recurrence of trisomy 21 among
women with an index trisomy 21, classiﬁed by age at the
index trisomy and age at a subsequent prenatal diagno-
sis. For comparison with previous analyses and to ensure
adequate sample size, we stratiﬁed cases dependent on
whether the index trisomy occurred at age !30 years or
30 years. Whereas there is no signiﬁcant difference
between the SMRs in the two age groups ( ), thePp .15
SMR is twice as high (4.6 vs. 2.1) in the women who
had their ﬁrst trisomy at a younger age. For women with
both index pregnancy and prenatal diagnosis at age !30
years, the recurrence risk is eight times that expected,
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Table 5
Recurrence of Trisomy 21: Index Pregnancy at Maternal Age 30 Years
Maternal Age and Sample
No. of Prenatal
Diagnoses
Expected No.
of Trisomy 21
Observed No.
of Trisomy 21 SMRa 90% CI Pb
Prenatal diagnosis at age 30–34 years:
Genzyme 126 .320 1 3.3 .3–15.5 .274
Sainte-Justine 71 .164 0 0 .0–18.2 1.0
Total prenatal diagnoses 197 .484 1 2.1 .2–10.2 .274
Prenatal diagnosis at age 35–39 years:
Genzyme 337 2.458 2 .8 .2–2.6 .704
Sainte-Justine 101 .734 6 8.2 4.1–16.4 .0001
Total prenatal diagnoses 438 3.192 8 2.5 1.4–4.6 .017
Prenatal diagnosis at age 40–44 years:
Genzyme 145 3.453 6 1.7 .9–3.5 .136
Sainte-Justine 20 .511 1 2.0 .2–9.7 .400
Total prenatal diagnoses 165 3.964 7 1.8 .9–3.3 .107
All prenatal diagnoses:
Genzyme 608 6.231 9 1.4 .6–2.5 .178
Sainte-Justine 192 1.409 7 5.0 2.6–9.2 .001
Total prenatal diagnoses 800 7.640 16 2.1 1.4–3.2 .005
a Observed/expected.
b One-tailed exact P value.
Table 6
Recurrence of the Same Trisomy (Homotrisomy): All Trisomies
Index Karyotype
and Sample
No. of Prenatal
Diagnoses
No. Expected with
Same Trisomy
No. Observed with
Same Trisomy SMRa 90% CI Pb
Trisomy 21:
Genzyme 711 6.370 11 1.7 1.0–2.8 .06
Sainte-Justine 674 2.144 9 4.2 2.3–7.2 .0004
Total Trisomy 21 1,385 8.514 20 2.4 1.6–3.4 .0005
Trisomy 18:
Genzyme 252 .467 0 0.0 .0–6.4 1.00
Sainte-Justine 139 .109 1 9.2 1.0–45.4 .10
Total Trisomy 18 391 .576 1 1.7 .2–8.6 .43
Trisomy 13:
Genzyme 138 .098 1 10.2 1.1–50.6 .09
Sainte-Justine 77 .019 0 0.0 .0–157.6 1.00
Total Trisomy 13 215 .117 1 8.6 .9–42.3 .11
XXX/XXY:
Genzyme 42 .106 0 0
Sainte-Justine 6 .012 0 0
Total XXX/XXY 48 .118 0 0 .0–25.4 1.00
All non-21 trisomies 654 .811 2 2.5 .7–8.0 .20
All viable trisomies:
Genzyme 1,143 7.041 12 1.7
Sainte-Justine 896 2.272 10 4.4
Total trisomies 2,039 9.313 22 2.4 1.7–3.4 .0003
a Observed/expected.
b One-tailed exact P value.
given maternal age alone (90% CI 3.6–18.6), and sig-
niﬁcantly different from the SMR of 2.1 (90% CI 1.4–
3.3) in women aged 30 years at both pregnancies
( ).Pp .01
Table 6 shows recurrence of the same trisomy for all
types of potentially viable index trisomies. For each tri-
somy except X-aneuploidy, the number of observed tri-
somies exceeds that expected on the basis of age alone.
For trisomy 21, the SMR is 2.4 (90% CI 1.6–3.4; Pp
). For the other trisomies, small numbers of cases.0005
lead to very large CIs about the SMR. For trisomies 18,
13, and X-aneuploidy, SMRs are 1.7 (90% CI 0.2–8.6),
8.6 (90% CI 0.9–42.3), and 0 (90% CI 0–25.4), respec-
tively. After combination of all viable trisomies except tri-
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Table 7
Recurrence of a Different Trisomy (Heterotrisomy)
Index Karyotype
and Sample
No. of Prenatal
Diagnoses
Expected No.
with Other
Viable Trisomy
Observed No.
with Other
Viable Trisomy SMRa 90% CI Pb
Trisomy 21:
Genzyme 711 3.671 7 1.9 1.0–3.6 .08
Sainte-Justine 674 1.448 5 3.4 1.7–7.3 .02
Total trisomy 21 1,385 5.119 12 2.3 1.5–3.8 .007
Trisomy 18:
Genzyme 252 2.402 1 .4 .0–2.1 .91
Sainte-Justine 139 .672 1 1.5 .2–7.4 .49
Total trisomy 18 391 3.074 2 .6 .2–2.1 .81
Trisomy 13:
Genzyme 138 1.752 1 .6 .1–2.8 .83
Sainte-Justine 77 .334 3 9.0 3.3–23.9 .005
Total trisomy 13 217 2.086 4 1.9 .8–4.3 .16
XXX/XXY:
Genzyme 54 .828 0 0 .0–3.6 1.00
Sainte-Justine 6 .059 0 0 .0–5.7
Total XXX/XXY 60 .887 0 0 .0–3.4 1.00
All viable trisomies
Genzyme 1,155 8.653 9 1.0 .6–1.8
Sainte-Justine 896 2.513 9 3.6 2.0–6.2
Total viable trisomies 2,051 11.166 18 1.6 1.1–2.4 .04
Nonviable trisomies:
Trisomy 16 (G) 125 1.682 2 1.2 .3–3.8 .50
Other trisomies 264 4.373 9 2.1 1.1–3.6 .03
All nonviable trisomies 389 6.055 11 1.8 1.1–3.0 .04
Total trisomies 2,442 17.221 29 1.7 1.2–2.3 .006
Triploidy and 45,X 414 3.124 3 1.0 .3–3.9 .60
a Observed/expected.
b One-tailed exact P value.
somy 21, the SMR is 2.5 (90% CI 0.7–78.0; ).Pp .20
When all viable trisomies are included, the SMR is 2.4
(90% CI 1.7–33.4; ).Pp .0003
Heterotrisomy
Table 7 shows the observed and expected numbers of
viable trisomies (13, 18, 21, and X-aneuploidy) that are
different from the index case. When the index case is
trisomy 21, the SMR is 2.3 (90% CI 1.5–3.8; Pp
). The SMRs are similar for women aged !30 years.007
and 30 years at the time of the index trisomy 21 (table
8). For index trisomy 13, trisomy 18, and X-aneuploidy,
the SMRs are 0.6 (90% CI 0.1–2.4), 1.9 (90% CI 0.5–
4.9), and 0 (90% CI 0–4.5), respectively. There is no sig-
niﬁcant heterogeneity in the SMRs among the four tri-
somy classes ( ). After combination of all casesPp .15
with an index viable trisomy, the SMR for a different
viable trisomy is 1.6 (90% CI 1.1–2.4; ).Pp .04
In the Genzyme sample, we could examine prenatal
diagnoses subsequent to an index karyotyped sponta-
neous abortion with a trisomy other than 13, 18, 21,
or X-aneuploidy. In this situation, the SMR for a sub-
sequent viable trisomy is 1.8 (90% CI 1.1–3.0; Pp
) (table 7). Because trisomy 16, the most frequent.04
trisomy in spontaneous abortions, may involve different
mechanisms of origin than do other trisomies (Hassold
and Hunt 2001), we examined trisomy 16 separately. For
trisomy 16 index pregnancies, the SMR for a subsequent
viable trisomy is 1.2 (90% CI 0.3–3.8; ); it doesPp .50
not differ signiﬁcantly from the SMR of 2.2 (90%CI 1.1–
3.6) for all other index nonviable trisomies combined.
Since the estimates of the SMR for viable and non-
viable trisomies are not signiﬁcantly different, we com-
bined the data to estimate that the overall SMR for het-
erotrisomy is 1.7 (90% CI 1.2–2.3; ).Pp .006
We also estimated the risk of a subsequent viable tri-
somy in 414 cases for which the index pregnancy was
either 45,X or triploid (table 7). The SMR is 1.0 (90%
CI 0.3–3.9; ), indicating no increased risk overPp .60
the age-related rate of trisomy.
Heterogeneity between Samples
For both homotrisomy and heterotrisomy recurrence,
the SMR is usually greater in the Sainte-Justine sample
than in the Genzyme sample. With the exception of the
combined risk for recurrence of heterotrisomy, the dif-
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ferences between the samples are not statistically signiﬁ-
cant ( ). We have therefore presented the data forP 1 .05
the two samples separately, but we have used the com-
bined sample for our ﬁnal estimation of the SMRs.
The observed trend may merely reﬂect random varia-
tion, given the small number of subsequent trisomies.
Another possibility is that the disparities relate to different
methods of ascertainment. In Sainte-Justine, the reason
for testing was recorded before amniocentesis. However,
a trisomic prenatal diagnosis could have triggered post
hoc disclosure and recording of a previous trisomy. Dif-
ferential disclosure would inﬂate the recurrence risk. In
the Genzyme sample, data derive from linked laboratory
records for which the information on a previous trisomy
does not depend on the woman’s report. A second pos-
sible source of difference between the samples is the na-
ture of the index trisomies, which included live births in
the Sainte-Justine but not in the Genzyme sample.
Although recurrence risks are generally higher in the
Sainte-Justine sample, the Genzyme sample alone pro-
vides estimates of the SMRs of 1.7 for homotrisomy and
1.9 for heterotrisomy after trisomy 21. The statistically
signiﬁcant increase in risk ( ) for a viable tri-SMRp 1.8
somy following a nonviable trisomy in a spontaneous
abortion derives only from the Genzyme sample.
Discussion
Homotrisomy
Our North American data from prenatal diagnoses
show a signiﬁcant increase in risk for trisomy 21 after
a previous trisomy 21; the increase is greater for women
with their ﬁrst trisomy at age !30 years. These ﬁndings
are, for the most part, compatible with those from one
other large study, based on European amniocentesis data
(Stene et al. 1984; Warburton et al. 1987).
Since our results for recurrence of trisomy 21 do not
differ signiﬁcantly from those from the European data,
we have combined the two data sets in table 9 to provide
the best estimates of risk. The highest SMR (8.2) is found
for women with both their index trisomy 21 and their
prenatal diagnosis at age !30 years. The increased risk
is lower ( ) when the index trisomy occurs atSMRp 2.2
age !30 years but the prenatal diagnosis occurs at age
30 years. For women with both the index and prenatal
diagnosis at age30 years, the SMR is 1.6 (90% CI 1.1–
4.1). An increase in thematernal age–related risk for older
women was not seen in the European data alone.
Although the smaller sample size limits conclusions,
the data suggest a similarly increased risk for repeating
viable trisomies other than 21. In our sample, the SMR
for homotrisomy is 2.5 (90%CI 0.7–8.0) when trisomies
13 and 18 and the sex chromosome trisomies are com-
bined. The European sample provided no data on this
issue.
Heterotrisomy
Our data indicate an increased risk for recurrence of
a different trisomy subsequent to a trisomic pregnancy.
The SMR for heterotrisomy is 2.3 (90% CI 1.5–3.8)
after an index trisomy 21 and is 1.6 (90% CI 1.1–2.4)
when all types of index viable trisomies are combined.
In addition, in the Genzyme sample, we could also ex-
amine prenatal diagnoses following a spontaneous abor-
tion with a nonviable trisomy other than 13, 18, or 21.
In this case, the SMR for a subsequent viable trisomy
at prenatal diagnosis is 1.8 (90% CI 1.1–3.0; ).P ! .04
The similarity of the SMRs after a previous viable tri-
somy and after a previous trisomic spontaneous abortion
suggests that the increased risk relates to trisomies in
general. Although the data raise the possibility that tri-
somy 16 is an exception, the sample size is not sufﬁcient
to allow this conclusion.
The European study provides data on heterotrisomy
risk only after an index pregnancy with trisomy 21. In
table 10, we combine the two data sets for the best
estimate of the SMR. For women with an index trisomy
21 at age !30 years, the SMR for a different viable
trisomy is 2.4 (90% CI 1.4–4.1). For women aged 30
years at the index trisomy 21, the SMR in the combined
data is 1.7 (90% CI 1.1–2.7). The risks do not differ
signiﬁcantly for the younger and older women.
Finally, the data do not indicate any increase in tri-
somy risk after a pregnancy with monosomy X or tri-
ploidy ( ; 90% CI 0.3–3.9; ).SMRp 1.0 Pp .60
Implications for Theories Concerning Origins of
Trisomy
The higher recurrence risk for trisomy 21 among
younger mothers can be explained if gonadal trisomy
mosaicism accounts for a larger proportion of recur-
rences in women whose maternal age–related risk is low.
Existing data suggest this is so. Combining results of the
studies of Pangalos et al. (1992) and James et al. (1998),
parental mosaicism was demonstrable in six of nine sib-
ships with multiple cases of trisomy 21 born to mothers
aged !35 years and in only one of eight such sibships
when the mother was aged 135 years. The existence of
gonadal mosaicism also predicts a higher recurrence risk
for homotrisomy than for heterotrisomy. Although the
SMRs are not signiﬁcantly different (2.4 for homotri-
somy and 1.7 for heterotrisomy), the results are consis-
tent with this prediction.
The signiﬁcantly increased risk for heterotrisomy in-
dicates that the risk of meiotic nondisjunction at a given
maternal age varies among women, with some at a
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Table 8
Recurrence of a Different Viable Trisomy after Index Trisomy 21, for Women Classiﬁed by Age at
Index Trisomy
Maternal Age and Sample
No. of
Prenatal
Diagnoses
No. Expected
with Other
Viable Trisomy
No. Observed
with Other
Viable Trisomy SMRa 90% CI Pb
Index trisomy 21 at age !30 years:
Genzyme 103 .137 0 0 .0–21.8 1.0
Sainte-Justine 482 .651 2 3.1 .8–9.9 .139
Total prenatal diagnoses 585 .788 2 2.5 .7–8.2 .187
Index trisomy 21 at age 30 years:
Genzyme 608 3.534 7 2.0 1.0–3.7 .068
Sainte-Justine 192 .797 3 3.8 1.4–10.0 .047
Total prenatal diagnoses 800 4.331 10 2.3 1.4–3.9 .013
a Observed/expected.
b One-tailed exact P value.
Table 9
Comparison of European and North American Data: Recurrence of Trisomy 21
Category
North American Data
(2003)
European Data
(1987) Combined Data
Index trisomy 21 at age !30 years, PND at age !30 years:
No. of PNDa 422 1,661 2,083
No. of expected trisomy 21 .48 1.6 2.08
No. of observed trisomy 21 4 13 17
SMRb 8.2 8.1 8.2
90% CI 3.6–18.8 5.0–12.8 5.4–12.3
Index trisomy 21 at age !30 years, PND at age 30 years:
No. of PNDa 163 888 1051
No. of expected trisomy 21 .39 2.4 2.79
No. of observed trisomy 21 0 6 6
SMRb .0 2.5 2.2
90% CI 0–7.7 1.2–5.0 1.1–4.3
Total with index trisomy 21 at maternal age !30 years:
No. of PNDa 585 2,549 3,134
No. of expected trisomy 21 .87 4.0 4.87
No. of observed trisomy 21 4 19 23
SMRb 4.6 4.8 4.7
90% CI 2.0–10.4 3.3–7.0 3.3–6.7
Index trisomy 21 at maternal age 30 years:
No. of PNDa 800 922 1,722
No. of expected trisomy 21 7.64 6.7 14.34
No. of observed trisomy 21 16 7 23
SMRb 2.1 1.0 1.6
90% CI 1.4–3.2 .5–2.0 1.1–4.1
a PND p prenatal diagnosis.
b Observed/expected.
higher risk for nondisjunction in general. This conclu-
sion is compatible with most hypotheses concerning the
mechanism of nondisjunction and the maternal-age as-
sociation, including variation in biological aging of the
ovary (Kline et al. 2000; Beever et al. 2003), genetic varia-
tion in rates of recombination or genes involved in oo-
cyte maintenance or division (Zwick et al. 1999; Brown
et al. 2000), and environmental exposures (Hunt et al.
2003),
Implications for Genetic Counseling
The expected rate of trisomy recurrence for a given
woman should be calculated as the SMR multiplied by
the age-related risk. The overall risk for recurrence of a
viable trisomy includes both the risk of homotrisomy and
the risk of heterotrisomy. In table 11, we summarize the
SMRs for selected characteristics at the index pregnancy
and at age of prenatal diagnosis. We include the actual
rate of trisomy at prenatal diagnosis (per 1,000) observed
in our data, to indicate the approximate magnitude of
the risks involved. However, the actual rate of trisomy
observed in any sample will depend on the maternal-age
distribution and the gestational age of the pregnancies
(i.e., whether amniocentesis, chorionic villus sampling,
or live birth).
Two ﬁndings in our study indicate different risks for
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Table 10
Comparison of European and North American Data: Recurrence of Other Trisomies
after Trisomy 21
Category
North American Data
(2003)
European Data
(1987) Combined Data
!30 years:
No. of PNDa 585 2,549 3,184
No. of expected other trisomies .79 3.4 4.19
No. of observed other trisomies 2 8 10
SMRb 2.5 2.4 2.4
90% CI .7–8.2 1.3–4.3 1.4–4.1
30 years:
No. of PNDa 800 922 1,722
No. of expected other trisomies 4.33 3.7 8.03
No. of observed other trisomies 10 4 14
SMRb 2.3 1.1 1.7
90% CI 1.4–3.9 .5–2.4 1.1–2.7
All maternal ages combined:
No. of PNDa 1,385 3,437 4,906
No. of expected other trisomies 5.12 7.1 12.22
No. of observed other trisomies 12 12 24
SMRb 2.3 1.7 2.0
90% CI 1.5–3.8 1.1–2.8 1.4–2.8
a PND p prenatal diagnosis.
b Observed/expected.
Table 11
Estimated Risks for Recurrence of Trisomy at Prenatal Diagnosis
INDEX TRISOMY TYPE AND MATERNAL AGE
RISK OF RECURRENCE FOR
Same Trisomy Other Viable Trisomy
Trisomy 21 at !30 years, PNDa at !30 years:b
Multiple of age-related risk (SMR) 8.2
Rate/1,000c 8
Trisomy 21 at !30 years, PNDa at 130 years:b
Multiple of age-related risk (SMR) 2.2
Rate /1,000c 6
All, trisomy 21 at !30 years:b
Multiple of age-related risk (SMR) 4.7 2.4
Rate/1,000c 7 3
Trisomy 21 at 130 years:b
Multiple of age-related risk (SMR) 1.6 1.7
Rate/1,000, PNDa at maternal age 30–34 years:c 5 8d
Rate/1,000, PNDa at maternal age 35–39 years:c 18
Rate/1,000, PNDa at maternal age 40 years:c 42
Trisomies 13, 18, XXX, and XXY
Multiple of age-related risk (SMR) 2.5 1.6
Rate/1,000c 3 9
Nonviable trisomy in spontaneous abortion:
Multiple of age-related risk (SMR) 1.8
Rate/1,000c 6
a PND p prenatal diagnosis.
b Based on tables 9 and 10.
c Based on observed numbers in tables 7–10.
d Ages combined.
trisomy recurrence from those commonly used in genetic
counseling. First, we conclude that, after a previous preg-
nancy with trisomy 21, the risk of a subsequent trisomy
21 is greater than the age-related risk for women whose
ﬁrst trisomy occurred at age 30 years. In practice, this
new information is likely to have few implications.
Women aged 35 years are offered prenatal diagnosis
regardless of history. A previous trisomy 21 is likely
to cause anxiety sufﬁcient to lead younger women to
seek prenatal diagnosis. However, a higher risk esti-
mate might lead a woman to choose ﬁrst-trimester
screening and/or chorionic villus sampling rather than
amniocentesis.
Second, our data suggest that there is a 1.6- to 1.8-
fold increase in risk for a different viable trisomy, both
after a previous trisomy 13, 18, or 21 and after a pre-
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vious nonviable trisomy detected in a spontaneous abor-
tion. This inference differs from our interpretation of
previous data on heterotrisomy recurrence, derived from
women with two karyotyped spontaneous abortions
(Warburton et al. 1987). The increased risk may provide
an indication for ﬁrst-trimester screening or prenatal di-
agnosis among women aged !35 years known to have
had a trisomic spontaneous abortion.
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